Skip to main content

Motus GI Hosting Key Opinion Leader Call on Improving Endoscopy Outcomes with the Pure-Vu® System

Written by Customer Service on . Posted in Public Companies.

FORT LAUDERDALE, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will host a key opinion leader (KOL) call on improving inpatient endoscopy outcomes with the Pure-Vu® system on Friday, October 16, 2020.
The webinar will feature a presentation by KOL Seth Gross, MD, NYU Langone, who will discuss:The unmet needs and challenges associated inpatient colonoscopyThe benefits to patients in reducing time in the hospital, especially during the COVID-19 pandemicMitigating increasing costs to hospitals due to delayed / incomplete procedures
Dr. Gross will be available to answer questions following the formal presentation.Motus GI’s management team will also provide an update on the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy. The system is currently in more than 20 major U.S. hospitals, including NYU Langone Medical Center, Cleveland Clinic, UC-Irvine Health, UCLA Health, University of Texas, Memorial Hermann and Geisinger Medical Center.To register for the call, please click here.Seth Gross, MD is Associate Professor of Medicine at the NYU Grossman School of Medicine and Clinical Chief of the Division of Gastroenterology & Hepatology at NYU Langone Health. As a gastroenterologist, Dr. Gross specializes in advanced endoscopic procedures. His clinical practice is focused on the prevention, diagnosis, and treatment of gastrointestinal pre-cancerous conditions and cancers, such as esophageal cancer, colorectal cancer, and pancreatic cancer. Dr. Gross’ research interests lie in the area of gastrointestinal malignancies as well as quality and innovation in endoscopy.Dr. Gross oversees the clinical programming and quality initiatives for the Division of Gastroenterology & Hepatology at NYU Langone Health. He is a member of U.S. Multi-Society Task Force on Colorectal Cancer He is Chair of International Affairs Committee for the American College of Gastroenterology (ACG), reimbursement advisor to the American Medical Association for the ASGE, and an associate editor for the journal Gastrointestinal Endoscopy.About Motus GIMotus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.